State Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Phytomedicine. 2023 Jan;108:154517. doi: 10.1016/j.phymed.2022.154517. Epub 2022 Oct 22.
Angiogenesis is a pathological phenomenon contribute to the development of chronic liver diseases, and anti-angiogenic therapy is an effective strategy to alleviate liver fibrosis. Carthami flos, a medicinal and edible herb, has the effects of improving blood circulation and regulating angiogenesis. However, the anti-angiogenic effect of Carthami flos in liver fibrosis remains unknown.
We investigated the protective effect and therapeutic mechanism of Carthami flos extract (CFE) on carbon tetrachloride (CCl)-induced liver fibrosis in mice. The liver injury and collagen deposition were observed and evaluated by conducting HE, Masson, and Sirius red staining, testing the serum biochemical indexes (ALT, AST, ALP, γ-GT), and measuring the contents of HYP and four indexes of liver fiber (Col-IV, LN, HA, PC-III). Simultaneously, the expressions of α-SMA and Collagen-I were detected to determine the activation of hepatic stellate cells (HSCs). Subsequently, we measured the expressions of angiogenesis-related proteins such as PDGFRB, ERK1/2, p-ERK1/2, MEK, p-MEK, HIF-1α, VEGFA, VEGFR2, AKT and eNOS, and the mRNA levels of PDGFRB and VEGFA. Additionally, immunofluorescence staining and RT-qPCR assays were carried out to ascertain the expressions of continuous endothelial markers CD31, CD34 and vWF, and scanning electron microscope analysis was performed to observe the number of sinusoidal endothelial fenestrations.
Herein, we found that CFE could significantly reduce liver injury and collagen deposition, like the same effect of colchicine. CFE significantly alleviated CCl-induced liver injury and fibrosis, mainly manifested by reducing the levels of ALT, AST, ALP and γ-GT and decreasing the contents of HYP, Col-IV, LN, HA and PC-III. Additionally, CCl promoted the activation of HSCs by increasing the expressions of α-SMA and Collagen-I, while CFE could rectify the condition. Moreover, CFE treatment prevented the CCl-induced the up-regulation of PDGFRB, p-MEK, p-ERK1/2, HIF-1α, VEGFA, VEGFR2, AKT and eNOS, suggesting that CFE might provide the protection against abnormal angiogenesis. In the meantime, the gradual disappearance of sinusoidal capillarization after CFE treatment was supported by the decreased the contents of CD31, CD34 and vWF, as well as the increased number of sinusoidal endothelial fenestrae.
In this study, the reduction of collagen deposition, the obstruction of HSCs activation, the inactivation of angiogenic signaling pathways and the weakening of hepatic sinusoidal capillarization jointly confirmed that CFE might be promising to resist angiogenesis in liver fibrosis via the PDGFRB/ERK/HIF-1α and VEGFA/AKT/eNOS signaling pathways. Nevertheless, as a potential therapeutic drug, the deeper mechanism of Carthami flos still needs to be further elucidated.
血管生成是导致慢性肝病发展的病理性现象,抗血管生成治疗是缓解肝纤维化的有效策略。红花是一种药食同源的草药,具有改善血液循环和调节血管生成的作用。然而,红花在肝纤维化中的抗血管生成作用尚不清楚。
本研究旨在探讨红花提取物(CFE)对四氯化碳(CCl)诱导的小鼠肝纤维化的保护作用及治疗机制。通过 HE、Masson 和天狼猩红染色观察和评估肝损伤和胶原沉积,检测血清生化指标(ALT、AST、ALP、γ-GT),并测量 HYP 和肝纤维化四项(Col-IV、LN、HA、PC-III)的含量。同时,检测α-SMA 和 Collagen-I 的表达以确定肝星状细胞(HSCs)的激活情况。随后,我们检测了血管生成相关蛋白如 PDGFRB、ERK1/2、p-ERK1/2、MEK、p-MEK、HIF-1α、VEGFA、VEGFR2、AKT 和 eNOS 的表达,以及 PDGFRB 和 VEGFA 的 mRNA 水平。此外,我们进行了免疫荧光染色和 RT-qPCR 分析,以确定连续内皮标志物 CD31、CD34 和 vWF 的表达,并通过扫描电子显微镜分析观察窦状内皮窗的数量。
CFE 可显著减轻 CCl 诱导的肝损伤和纤维化,与秋水仙碱的作用相似。CFE 能显著降低 ALT、AST、ALP 和γ-GT 的水平,降低 HYP、Col-IV、LN、HA 和 PC-III 的含量,从而减轻 CCl 引起的肝损伤和纤维化。此外,CFE 可通过降低 PDGFRB、p-MEK、p-ERK1/2、HIF-1α、VEGFA、VEGFR2、AKT 和 eNOS 的表达,纠正 CCl 诱导的 HSCs 激活。同时,CFE 处理后,CD31、CD34 和 vWF 的含量降低,窦状内皮窗的数量增加,提示 CFE 可能通过 PDGFRB/ERK/HIF-1α 和 VEGFA/AKT/eNOS 信号通路对异常血管生成具有保护作用。
本研究通过降低胶原沉积、阻断 HSCs 激活、抑制血管生成信号通路以及减弱肝窦内皮窗的形成,共同证实 CFE 可能通过 PDGFRB/ERK/HIF-1α 和 VEGFA/AKT/eNOS 信号通路在肝纤维化中具有抗血管生成作用。然而,作为一种潜在的治疗药物,红花的更深层次机制仍需要进一步阐明。